Clinical Trial Update: Long-term Safety and Tolerability of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine [Phase 3]

View source ↗

Summary

Phase 3 trial update on long-term safety and tolerability of subcutaneous TEV-48125 for preventive treatment of migraine completed; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• TEV-48125

Snippet

Sponsor: Otsuka Pharmaceutical Co., Ltd. | Conditions: Migraine | Phase 3 | Status: COMPLETED | Results posted: 2021-07-16